Therefore, pre-screening NSCLC cells with wt-EGFR for BRG1 status can inform appropriate treatment decisions, offering patients the choice to receive either EGFR-TKI or AKT inhibitor therapy. Here, AKT1 is linked to non-small cell lung carcinoma.